Clinical Trial

PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This research is being done to find out if the study drug, 177Lu-PSMA-617, given before and during standard of care External Beam Radiation Therapy (EBRT) treatment, with a shorter course of Androgen Deprivation Therapy (ADT) (6 months) is (1) safe and effective compared to standard of care alone, and (2) can reduce the side effects caused by long-term (24 months) ADT in men with high risk localized prostate cancer.
Protocol Amendment History 4 changes
notable Primary completion pushed: 2032-07 -> 2032-08 2026-08-08
minor Completion pushed: 2033-07 -> 2033-08 2026-08-08
notable Primary completion pushed: 2032-04 -> 2032-07 2026-06-25
minor Completion pushed: 2033-04 -> 2033-07 2026-06-25
Trial Details
NCT Number NCT07550517
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: Novartis Pharmaceuticals
Conditions High-Risk Localized Prostate Cancer
Enrollment 60 participants
Start Date 2026-08
Primary Completion 2032-08 (estimated)
Study Completion 2033-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-07